LENZ Therapeutics Inc. (LENZ)
NASDAQ: LENZ
· Real-Time Price · USD
48.74
0.42 (0.87%)
At close: Oct 03, 2025, 3:59 PM
48.51
-0.47%
After-hours: Oct 03, 2025, 07:46 PM EDT
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 22, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Evert B. Schimmelpennink |
Contact Details
Address: 445 Marine View Avenue Solana Beach, California United States | |
| Website | https://www.lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001815776 |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary & Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Breianna Bowen | Vice President of Human Resources |
| David Choromanski | Vice President of Marketing |
| Domenick Porfidia | Vice President of Sales |
| James W. McCollum | Co-Founder & Director |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Melissa Rosness | Senior Vice President of Manufacturing Operations |
| Shawn Olsson | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2025 | 4 | Filing |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 22, 2025 | 4 | Filing |
| Sep 22, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 26, 2025 | 4 | Filing |
| Aug 20, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 19, 2025 | 4 | Filing |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |